GSK-J4 hydrochloride

Cell-permeable. An ethyl ester derivative of the JMJD3 selective histone demethylase inhibitor GSK-J1 (Cat. No. 2260-1, 5) (IC₅₀> 50 μM in vitro. When administered to human primary macrophages, GSK-J4 can reduce lipopolysaccharide (LPS)-induced proinflammatory cytokine production, most notably including that of TNFα (IC₅₀ = 9 µM).